Neurocrine Biosciences Analyst Price Targets

PRO

¿Por qué se mueve?:Neurocrine shares are trading higher after the company reported better-than...

Ganancias: Los beneficios de Q3 2026 se publicaron el lun nov 2nd, después del cierre del mercado

Conferencia telefónica: La conferencia telefónica más reciente comenzó a las 4:30 p. m., hace 1 día

Haz clic para ver el webcast

Neurocrine Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Neurocrine Biosciences (NBIX).

Price Target Range — 7 Quarters

Analyst Consensus — 22 Analysts

20Buy

2Hold

Consensus RatingBuy# Analysts22Avg. Consensus PT$202Upside to Avg. PT+22.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 3, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$210→$215
Nov 3, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$183→$185
Nov 3, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$187→$190
Nov 3, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$210→$220
Oct 16, 2026	Needham	Ami Fadia	Maintained	Buy	$204
Oct 12, 2026	BMO Capital	Evan Seigerman	PT Cut	Market Perform	$164→$150
Oct 6, 2026	Guggenheim	Delma Caiati	Assumes	Buy	$207
Sep 29, 2026	UBS	Ashwani Verma	PT Cut	Buy	$231→$214
Sep 11, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$182→$183
Sep 8, 2026	RBC Capital	Brian Abrahams	Maintained	Outperform	$198
Sep 3, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$249→$253
Aug 13, 2026	Morgan Stanley	Jeffrey Hung	PT Cut	Equal-Weight	$196→$182
Aug 3, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$200→$210
Aug 3, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$200→$213
Aug 3, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$185→$194
Jul 31, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$246→$249
Jul 31, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$195→$198
Jul 31, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$193→$196
Jul 31, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$200→$220
Jul 31, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$207→$210

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $183 to $185.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $187 to $190.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $210 to $220.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $204 price target.

Benzinga Newsdesk

PRO
BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and lowers the price target from $164 to $150.

Benzinga Newsdesk

Neurocrine Biosciences Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Neurocrine Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

PRO
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

PRO
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

PRO
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

PRO
Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

PRO
BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150

People Also Watch

People Also Watch

Neurocrine Biosciences Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Neurocrine Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

PRORBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

PROCanaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

PROPiper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

PRONeedham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

PROBMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

PRO
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

PRO
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

PRO
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

PRO
Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

PRO
BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150